Name: A 410099.1 amide-PEG2-amine-Boc
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Storage

Store at -20°C

Shipping

Room temperature in continental US; may vary elsewhere.

InChI Key

LEBUBVVDWZLBBX-SHHSPICZSA-N

Canonical SMILES

CN([C@@H](C)C(N[C@@H](C1CCCCC1)C(N2C[C@H](C[C@H]2C(N[C@@H]3CCCC4=CC=CC=C34)=O)NC(COCCOCCN)=O)=O)=O)C(OC(C)(C)C)=O

Pub Chem ID

146018938

Background Introduction

A 410099.1 amide-PEG2-amine-Boc is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation strategies, such as the development of PROTACs (Proteolysis Targeting Chimeras). By incorporating a PEG2 (polyethylene glycol) linker and functionalized amine/Boc protecting groups, this molecule offers excellent solubility and that essential balance between flexibility and stability, driving its utility in chemical biology and drug discovery applications.

Mechanism

The mechanism of A 410099.1 amide-PEG2-amine-Boc is centered around its role as a bifunctional connector in PROTACs. The E3 ligase ligand component binds an E3 ubiquitin ligase enzyme, while the amide-PEG2-amine linker provides optimal spatial arrangement and solubility. The PEG2 linker ensures flexibility and reduces steric hindrance, whereas the Boc-protected amine allows for further functionalization or deprotection depending on synthetic needs. In a PROTAC, this conjugate facilitates the recruitment of specific proteins to the cell's ubiquitination machinery, leading to selective ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

A 410099.1 amide-PEG2-amine-Boc serves as a key building block for assembling novel PROTACs and other heterobifunctional molecules aimed at targeted protein degradation. Its applications include: 1) Chemical biology research to understand protein function via rapid depletion; 2) Drug discovery—particularly the development of new therapeutics against undruggable targets; 3) Synthesis of custom bifunctional molecules for mechanistic studies or screening campaigns involving targeted degradation pathways. The flexible PEG2 linker and modifiable Boc-amine group make this conjugate highly versatile for various synthetic and biological workflows.

• Amide-PEG2 linker ensures excellent water solubility and flexibility for superior PROTAC design.
• Boc-protected amine functionality allows for easy selective deprotection and conjugation in targeted protein degradation research.

1. [Hypoglycemic sulfonylurea metabolites: clinical interest. Experiences with glibenclamide in the rat

H Samimi, L Loutan, L Balant, M Tillolès, J Fabre Schweiz Med Wochenschr. 1977 Sep 17;107(37):1291-6.

Glibenclamide, a hypoglycemic sulfonylurea, is extensively metabolized by the body and eliminated primarily in the form of its hydroxylated derivatives. The major metabolite, 4-trans-hydroxy-glibenclamide, is usually cleared rapidly from the bloodstream, but in certain pathological states (e.g. renal failure) blood levels of this product may increase. A protocol therefore was designed to test the hypoglycemic potency of this important metabolite in rats. Various quantities were injected intraperitoneally, and alterations in blood glucose concentrations were measured during a 5-hour period and compared to those in animals similarly treated with glibenclamide and in saline-injected controls. Using the dose capable of decreasing blood glucose levels by 30% (ED30) as a comparative index, it was observed that the metabolic has a marked hypoglycemic activity; though 6--7 times less potent than the parent drug, 4-trans-hydroxy-glibenclamide is nevertheless more potent than tolbutamide. Thus, while the glibenclamide metabolite probably has little influence on blood glucose when its clearance is normal, this product may exert marked effects if allowed to accumulate in the blood, as for example in renal failure. Finally, the role of such sulfonylurea metabolites should be taken into account when attempting to explain the occasional excessive and sustained hypoglycemia which occurs in some diabetic patients treated with these drugs.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂